Insider buys 230,000 NBP shares at depressed valuation amid sustained price weakness
An insider at NovaBridge Biosciences executed a substantial open-market purchase of over 230,000 shares, representing a meaningful capital commitment at a time when the stock is trading significantly below its recent highs and has declined sharply over recent months. The purchase price sits slightly above the stock's 52-week low, suggesting the insider is deploying capital into genuine weakness rather than riding momentum—a contrarian signal that often precedes recoveries when insiders have conviction. This aggressive buying into a beaten-down biotech name warrants close examination of whether the insider has insight into near-term catalysts, pipeline developments, or a genuine belief in undervaluation. The company's market capitalization context indicates this is a microcap biotech where insider conviction can move share price meaningfully, making this transaction particularly noteworthy for retail investors seeking conviction-based signals.